Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arcellx, Inc.

Latest From Arcellx, Inc.

J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In

They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.

ImmunoOncology Cancer

BMS Forges Ahead With Next Round Of Multiple Myeloma Therapies

The drug maker provided updates at ASH on newer agents, including a GPRC5D-directed CAR-T therapy, a member of the CELMoD class and its entry into an increasingly crowded BCMA bispecific ring.

Clinical Trials Business Strategies

A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T

Anito-cel showed strong efficacy in heavily pretreated patients despite characteristics predicting poorer performance, but none of the atypical neurotoxicities that have appeared with other BCMA CAR-Ts.

Clinical Trials ImmunoOncology

Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas

The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.

Deals ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy